Advertisement

What Are the Complications of Home IBD Medications?

  • Kathryn VossEmail author
Chapter

Abstract

Inflammatory bowel disease may be treated with a variety of medications depending on the severity of disease, location of disease, and goals of treatment. Common medications include systemic and local glucocorticoids, antibiotics, 5-aminosalicylates, immunomodulatory agents, and biologic therapies. Each medication class carries distinct and important side effects.

Keywords

Glucocorticoids Antibiotics Aminosalicylates Immunomodulators Biologics Inflammatory bowel disease Side effects Adverse drug reactions 

References

  1. 1.
    Curtis J. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–6.CrossRefGoogle Scholar
  2. 2.
    Etminan M. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology. 2014;83(14):1261.CrossRefGoogle Scholar
  3. 3.
    Khaliq Y. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404.CrossRefGoogle Scholar
  4. 4.
    Kang J. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59(1):122–6.CrossRefGoogle Scholar
  5. 5.
    Carroll M. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(8):3903–9.CrossRefGoogle Scholar
  6. 6.
    Deshpande A. Community-associated clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951.CrossRefGoogle Scholar
  7. 7.
    Box SA. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol. 1997;36(3):382–6.CrossRefGoogle Scholar
  8. 8.
    Farr M. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine. Drugs. 1986;32(Suppl 1):49–53.CrossRefGoogle Scholar
  9. 9.
    Schroeder K. Is mesalamine safe? Gastroenterol Hepatol (NY). 2007;3(11):878–9.Google Scholar
  10. 10.
    Chaparro M. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19(7):1404–10.CrossRefGoogle Scholar
  11. 11.
    Beaugerie L. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.CrossRefGoogle Scholar
  12. 12.
    Te HS. Hepatic effects of long-term methotrexate use in treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95(11):3150.CrossRefGoogle Scholar
  13. 13.
    Burdmann EA. Cyclosporine nephrotoxicity. Semin Nephrol. 2003;23(5):465–76.CrossRefGoogle Scholar
  14. 14.
    Hoorn EJ. The cacineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17(10):1304–9.CrossRefGoogle Scholar
  15. 15.
    Eidelman BH. Neurologic complications of FK 506. Transplant Proc. 1991;23(6):3175–8.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet. 1994;344(8920):423–8.Google Scholar
  17. 17.
    Hojo M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–4.CrossRefGoogle Scholar
  18. 18.
    Strangfield A. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914–20.CrossRefGoogle Scholar
  19. 19.
    Cheifetz A. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenerol. 2003;98(6):1315–24.CrossRefGoogle Scholar
  20. 20.
    Hastings R. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62(6):764.CrossRefGoogle Scholar
  21. 21.
    Cleynen I. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22.CrossRefGoogle Scholar
  22. 22.
    Gabriel SE. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis? Arthritis Rheum. 2008 Mar;58(3):637–40.CrossRefGoogle Scholar
  23. 23.
    Dreyer L. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish multiple sclerosis registry. Ann Rheum Dis. 2016;75(4):785–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.MedStar Georgetown University and Washington Hospital CenterWashington, DCUSA

Personalised recommendations